ITGB1 Gene Leukocyte Adhesion Deficiency (LAD) Genetic Test

Executive Summary & Core Metrics

This advanced genetic test provides a definitive molecular diagnosis for leukocyte adhesion deficiency by sequencing the entire coding region of the ITGB1 gene using Next‑Generation Sequencing (NGS), ensuring over 99.9% diagnostic sensitivity. It is conducted under the strict quality standards of ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) and overseen by DHA‑licensed specialists.

✔ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
✔ Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (Available daily from 8 AM to 11 PM).
✔ Clinical Guidance: Telephonic Post‑Test Clinical Interpretation by DHA‑licensed genetics experts.
✔ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Compliant with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of ICT in Health Fields.

Test Overview & Methodology

The ITGB1 Gene Leukocyte Adhesion Deficiency Genetic Test sequences the entire coding region of the integrin beta‑1 gene using Next‑Generation Sequencing (NGS) with deep coverage of all exons and flanking intronic regions. This test identifies pathogenic variants that cause a rare primary immunodeficiency characterized by recurrent infections, defective wound healing, and persistent leukocytosis. A mandatory pre‑test genetic counselling session and a documented family pedigree are required prior to sample collection. The ordering physician must provide the patient’s detailed clinical history for accurate interpretation.

Feature	Our NGS Test	Alternative Single‑Gene Test
Methodology	Next‑Generation Sequencing (deep coverage, all exons ± flanking introns)	Sanger sequencing (limited to specific known hotspots)
Analytical Sensitivity	>99.9% (single nucleotide, small indels)	~99% for targeted regions only
Turnaround Time	3–4 Weeks	4–6 Weeks
Physician Support	Post‑test clinical interpretation call included	Often raw data only

Physician Insight & Safety Protocols

As a clinical geneticist, I understand that a suspected leukocyte adhesion deficiency diagnosis can be challenging for families. This NGS test provides a definitive molecular result; however, a negative finding does not exclude all forms of immunodeficiency. Clinical correlation with infection history remains critical. I strongly recommend pre‑ and post‑test genetic counselling to interpret findings in the context of the patient's health trajectory.

— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA License: 9294403

⚠️ Medication Warning: Do not discontinue any prescribed medication (including antibiotics or prophylactic drugs) without consulting your treating physician. This test provides genetic confirmation only and does not replace ongoing clinical management.

🏥 Safety Exclusion Criteria & Emergency Red Flags

Exclusion: This test cannot be performed on patients who have received a bone marrow transplant within the last 6 months due to donor DNA interference.
ER Red Flag: If you or your child develops a high fever (>38.5°C), severe respiratory distress, or signs of sepsis during the waiting period, seek emergency medical care immediately – do not delay for test results.
Important: This assay does not replace a clinical immunological work‑up; a normal result does not exclude all forms of LAD.

Patient FAQ & Clinical Guidance

1. What is the ITGB1 gene and how does it relate to leukocyte adhesion deficiency?

The ITGB1 gene encodes integrin beta‑1, a protein essential for white blood cell adhesion and migration. Inherited mutations cause a rare primary immunodeficiency marked by recurrent bacterial and fungal infections, persistent leukocytosis, and impaired wound healing.

2. How is the sample collected and what is the turnaround time?

A DHA‑licensed phlebotomist performs a painless home blood draw or uses a DNA collection card. The sample is transported under strict cold‑chain protocol and processed at our ISO‑accredited laboratory. Results are delivered within 3–4 weeks.

3. Will my insurance cover this genetic test in the UAE?

Many UAE health insurers cover medically necessary genetic testing for primary immunodeficiencies. We verify your policy instantly via WhatsApp and offer direct billing; you only pay the co‑pay, if any.

4. What pre‑test requirements must be fulfilled?

A mandatory genetic counselling session and a documented family pedigree are required before sample collection. The ordering physician must provide a detailed clinical history to ensure accurate interpretation of results.

UAE Regulatory & Data Privacy Adherence

This test is performed in full compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient data is encrypted and stored securely, with access restricted to authorized medical personnel. Clinical safety and patient consent follow Federal Decree‑Law No. 4 of 2016 on Medical Liability. DNA Labs UAE is a licensed healthcare facility under the Dubai Health Authority (License No. 1143).

Clinical & Logistical Metadata

Test Name	ITGB1 Gene Leukocyte Adhesion Deficiency (LAD) Genetic Test
Price (AED)	2,800 AED
Turnaround Time	3–4 Weeks
Sample Type / Matrix	Blood (Whole Blood) – VIP Mobile Phlebotomy Home Collection Available
Methodology Used	Next‑Generation Sequencing (NGS) – Full coding region analysis
ICD-10-CM Code	D84.8, D72.0
LOINC Code	81247-9
DHA Facility License & Laboratory Address	DHA License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE